New research reveals that patients who come off blockbuster slimming jabs like semaglutide or tirzepatide may regain reduced body mass far faster than those who stop conventional diet and exercise programs.
Published data in a leading health publication shows that while overweight people often shed about a fifth of their total mass while using the jabs, the weight is regained at an average rate of 0.8 kg per month after stopping.
"Users buying these medications must be cognizant of the risk of fast rebound weight gain when the treatment ends," cautioned researcher Dr. Susan Jebb.
Such speed of regain implies a return to starting mass in about a year and a half.
Analyzing Treatments
The research, which looked at 37 of trials involving over 9,000 of patients, contrasted the results of these new drugs with other pills.
Researchers point out that people who lose weight through diet and exercise generally have a less rapid creep back—approximately 0.1 kg a month—once they finish.
Understanding the Fast Rebound
Nutrition scientists suggest the mode of action of the jabs explains the accelerated weight return.
GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Long-term administration of GLP-1 levels far above than normal may cause the body to produce less of its endogenous hormone, and could reduce sensitivity to its effects," explained Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this GLP-1 'fix' leads to hunger is unsuppressed, making binge eating much more probable."
A Chronic Disease?
Medical guidelines advise the jabs for people with obesity-related health risks, alongside prescribed diet and exercise modifications.
A number of clinicians argue that, given the likelihood of weight regain, the therapy might need to be life-long.
This perspective is echoed by drug manufacturers, who say that the findings "underscore the long-term nature of obesity," akin to managing diseases like high blood pressure.
Patient Testimonies
Users who have stopped the jabs report a powerful return of cravings.
"I experienced a trigger flipping and you're instantly starving," described an individual.
This difficulty is worsened if patients have not developed lasting lifestyle or habit modifications during therapy.
Significant Adoption
Figures indicate that millions of people in the UK have tried weight-loss jabs in the last 12 months, with interest remaining high.
- Use is greater among females compared to men.
- The middle-aged demographic shows the greatest level of interest.
- Many obtain the drugs through private prescriptions rather than the NHS.
Finally, clinicians stress that while the jabs are powerful agents for weight loss, they are not a permanent cure and long-term success likely depends on combined lifestyle management.
